Watson Pharmaceuticals Generics Company Intelligence Report

Date: January 22, 2011
Pages: 36
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W348726B5DEEN

Download PDF Leaflet

Watson Pharmaceuticals Generics Company Intelligence Report
Watson Pharmaceuticals was founded in 1984 in Corona, California. The company has facilities across the USA, and in the UK and China. It vies with Barr and Mylan as the USA’s largest generic manufacturer.

Watson’s sales for 2009 stood at US$2,793.0 million, an increase of 10.2% over the US$2,535.5 million reported for 2008. Generic net revenues amounted to US$1,668.2 million, up by 13.2% over the US$1,474.3 million reported for 2008.

The company has always had a small branded business, introducing its first branded product in 1996. In February 2003, the FDA approved Oxytrol, the company’s oxybutin product. This is the first product Watson has fully developed from conception to manufacturing and distribution.

In March 2006, Watson announced it had entered into an agreement to acquire the outstanding stock of Andrx, in a deal worth some US$1.9 billion. The deal was completed in November 2006.

In June 2009, Watson announced plans to acquire the Arrow Group for US$1.75 billion in cash and stocks. The acquisition would give the firm commercial operations in over 20 countries. It closed in late 2009; Watson believes it will be a pivotal acquisition.



Watson Pharmaceuticals: owned properties
Watson Pharmaceuticals: leased properties
Watson to expand New Jersey headquarters
Watson provides business overview

Watson Pharmaceuticals: selected generic produc t portfolio

Watson Pharmaceuticals: selected brand product portfolio
Watson ANDA Approvals, January 2002 – September 2010
Recent product approvals
Losartan (US)
Amlodipine besylate / benazepril (US)
Drospirenone / ethinyloestradiol approval (US)
Anastrozole (US)
Tacrolimus (US)
Rivastigmine (US)
Fentanyl buccal (US, tentative)
Valacyclovir (US)
Atorvastatin (Cobalt Laboratories, Canada)
Metoprolol (US)
Watson gains diltiazem ER approval
Watson files ramelteon ANDA


Latest Quarterly Results, Q310
Watson Pharmaceuticals: quarterly results, in US$ millions
Latest Fiscal Year Results, 2009
Watson Pharmaceuticals: fiscal year results, in US$ millions
Segment Results
Global Generic Segment
Global Brand Segment
Distribution Segment
Watson Pharmaceuticals: product sales by segment, in US$ millions


Mergers, acquisitions and agreements
Watson signs authorised generic agreement with Ortho-McNeil-Janssen Pharmaceuticals
Watson and Moksha8 form marketing partnership for Brazil and Mexico
Watson enters biosimilar product development agreement with Itero
Watson completes acquisition of Crinone/Prochieve and Columbia shares
Watson sells stake in Taiwan's ScinoPharm
Watson secures marketing rights to Population Council's contraceptive ring
Watson and HRA Pharma enter novel oral contraceptive licensing agreement
Indoco licenses out technology to Watson Pharmaceuticals
Watson acquires Arrow Group
Watson and GeneraMedix reach sodium ferric gluconate licence agreement
Watson challenges rosuvastatin patents
Watson challenges guanfacine patents
Watson confirms rasagiline patent challenge
Watson settles oxymorphone litigation with Endo
Watson confirms brimonidine tartrate and timolol maleate ophthalmic patent challenge
Forest / Merz settle memantine litigation
Impax and Watson challenge sevelamer patents
Watson challenges raloxifene patents
Watson challenges niacin / simvastatin patents
Watson confirms sirolimus patent challenge
Watson confirms choline fenofibrate patent challenge
Teva files oestrogens lawsuit against Watson; companies reach Seasonale settlement
Ortho-McNeil loses patent challenge appeal
Companies settle pioglitazone challenges
Watson challenges oxymorphone patents
FTC faces another 'pay for delay' ruling setback
Watson files bupropion hydrobromide ANDA
Endo Pharmaceuticals in receipt of lidocaine patent challenge
Watson files ANDA for Duramed / Teva oral contraceptive
Watson initiates armodafinil challenge
Watson and Barr settle oxybutynin lawsuit
Watson initiates trospium chloride challenge

Skip to top

Ask Your Question

Watson Pharmaceuticals Generics Company Intelligence Report
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: